Evidence map›Paper›PMID 35604725›Full record

ArticleThe British journal of radiology2022

Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision.

Elles Mf van de Voort, Gerson M Struik, Sophia P van Streun, Cornelis Verhoef, Carin A Uyl-de Groot, Taco Mal Klem

Abstract read
In one paragraph

Article in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Mammary Gland Microbiota in Benign Breast Diseases.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elles Mf van de VoortDepartment of Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.ORCID 0000-0003-2392-9763
Gerson M StruikDepartment of Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
Sophia P van StreunDepartment of Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
Cornelis VerhoefDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Carin A Uyl-de GrootInstitute for Medical Technoloy Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Taco Mal KlemDepartment of Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAlthough vacuum-assisted excision (VAE) is a safe and effective alternative to surgical excision (SE), the latter is most commonly used for the management of benign and high-risk breast lesions. To evaluate the healthcare benefit of VAE, hospital costs and cosmetic outcome after VAE were compared to SE. Additionally, the impact of VAE implementation on hospital costs was investigated.

methodsThis was a single-centre retrospective cohort study with two cohorts: "VAE" and "SE". All patients with a benign or high-risk lesion excised by VAE or SE from January 2016 up to December 2019 were included. Cosmetic outcome was measured with the BCTOS-cosmetic subscale, and hospital costs were presented as mean (SD) and median (IQR).

resultsDuring the study period, 258 patients with 295 excised lesions were included. The initial procedure was VAE in 102 patients and SE in 156 patients. Hospital costs after (median € 2324) were significantly lower than before (median € 3,144) implementation of VAE (mean difference € 1,004,

conclusionsImplementing VAE as an alternative treatment option for benign and high-risk breast lesions resulted in a large decrease in hospital costs but a cosmetic benefit of VAE could not be demonstrated in this retrospective study. ADVANCES IN KNOWLEDGE: Costs associated with the complete patient pathway were included and not only VAE was compared to SE but also the before cohort was compared to the after cohort to demonstrate the benefit of VAE implementation in clinical practice. Additionally, cosmetic outcome was compared between VAE and SE using patient reported outcome measures.

Indexed as

Breast NeoplasmsHospital CostsBreastFemaleHumansPatient Reported Outcome MeasuresRetrospective StudiesVacuum

Identifiers

PMID35604725
PMCPMC10162056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.